Junhemeng Biopharmaceutical (Hangzhou) Co Ltd

09/14/2024 | Press release | Archived content

JHM Biopharmaceutical Begins Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke-Related Spasticity

JHM Biopharmaceutical Begins Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke-Related Spasticity

JHM Biopharmaceutical (Hangzhou) Co., Ltd. ("JHM") today announced the enrollment of its first patient in a clinical trial of its innovative, patented Recombinant Type A Botulinum Toxin. The trial, led by Huashan Hospital (affiliated to Fudan University), marks the official launch of neurological research in China using this treatment for adult stroke patients who suffer from upper limb spasticity.

Junhemeng Biopharmaceutical (Hangzhou) Co Ltd published this content on September 14, 2024, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 29, 2026 at 11:58 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]